Ibrutinib (Imbruvica) for Lymphoma

( Last Updated : July 17, 2019)

Generic Name:

Ibrutinib

Project Status:

Not filed

Manufacturer:

Janssen Canada Inc.

Brand Name:

Imbruvica

Project Line:

Reimbursement Review

Project Number:

N/A

Details

Tumour Type:

Lymphoma

Indications:

In combination with rituximab for Waldenstrom's Macroglobulinemia

Review Status:

Not Filed

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Clarification:

CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.